EndeavorOTC® Research Study in College Students

June 25, 2024 updated by: Akili Interactive Labs, Inc.
The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

University students face an increased risk of mental health challenges, as well as elevated stress due to the demands of managing coursework and social stress during a formative developmental period with increased independence. Consequently, there is a need for scalable, evidence-based interventions that can help university students manage their cognitive and emotional health. Through a partnership between Akili Interactive Labs and participating colleges, free 12-week access to AKL-T01 will be provided to any student interested in treatment for the duration of an academic semester, up to an N of 500 per site. This study will evaluate changes in participants across a range of clinical and functional outcomes, including cognitive functioning, academic outcomes, social functioning, attention and associated symptoms, and quality of life. The study will also evaluate user feedback and information on the usability of AKL-T01 through both quantitative and qualitative methods.

Study Type

Interventional

Enrollment (Actual)

69

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Cheektowaga, New York, United States, 14225
        • Villa Maria College
    • Vermont
      • Putney, Vermont, United States, 05346
        • Landmark College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Owns a personal Android or iOS device to access AKL-T01 treatment
  • Provides informed consent to participate in this study
  • Is 18 years of age or older

Exclusion Criteria:

  • Known photosensitive epilepsy, color blindness, and any physical limitation that would make engagement with an app-based digital intervention difficult
  • Has participated in the same study in previous semesters

Pregnant and nursing people are eligible to participate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
Participants receive immediate 12-week access to EndeavorOTC.
EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Other Names:
  • AKL-T01A
Experimental: Group 2
Participants receive 12-week access to EndeavorOTC 6-weeks after Group 1.
EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Other Names:
  • AKL-T01A

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Computerized Adaptive Test, Mental Health (CAT-MH®)
Time Frame: Baseline, Exit (Day 84)

Computerized Adaptive Test, Mental Health (CAT-MH®) is a distinct suite of computer adaptive tests that is based on multidimensional item response theory. The adult ADHD module is a dimensional severity measure of attention-deficit/hyperactivity disorder symptomatology for adults 18 and over. The number and selection of questions within the assessment varies as individuals' initial item responses are used to determine a provisional estimate of their standing on the measured trait to be used for subsequent item selection. Items are scored on a Likert scale of 1 (Not at all), 2 (Just a little), 3 (Somewhat), 4 (Quite a bit), and 5 (Very much).

Negative change in score indicates improvement in ADHD severity.

Baseline, Exit (Day 84)
PROMIS Cognitive Function v2.0 - Short Form
Time Frame: Baseline, Day 42, Day 84

The PROMIS Cognitive Function v2.0 short form consists of six questions about the respondent's cognitive function in the past 7 days rated on a Likert scale of 1-5, where 1=Very often (Several times a day) and 5=Never.

Higher score indicates higher levels of cognition. Positive change in score indicates improvement.

Baseline, Day 42, Day 84
PROMIS Satisfaction with Participation in Discretionary Social Activities (v1.0)
Time Frame: Baseline, Day 42, Day 84

The PROMIS Satisfaction with Participation in Discretionary Social Activities scale consists of 7 questions about the respondent's satisfaction in the past 7 days rated on a Likert scale of 1-5 where 1=Not at all and 5=Very much.

Higher score indicates more satisfaction. Positive change in score indicates improvement.

Baseline, Day 42, Day 84
General Academic Self-Efficacy scale (GASE)
Time Frame: Baseline, Day 42, Day 84

The GASE is a short and concise five-item measure of the longer form Academic self-efficacy (ASE) scale. The scale assesses a student's global belief in his or her ability to master the various academic challenges in an academic setting and is considered an essential antecedent of wellbeing and performance.

Higher score indicates more self-efficacy. Positive change in score indicates improvement.

Baseline, Day 42, Day 84
Mental Health Quality of Life Scale (MHQoL)
Time Frame: Baseline, Day 42, Day 84

The MHQoL is a standardized, validated self-report measure of quality of life that has been developed for use in people with mental health problems.18 It consists of 7-items covering self-image, independence, mood, relationships, daily activities, physical health, and future measured on a 4-point Likert scale ranging from "Very satisfied" to "Very dissatisfied," and an analogue scale from regarding psychological well-being where 0 = "worst imaginable psychological well-being" and 10 = "best imaginable psychological well-being."

Higher score indicates a better quality of life. Positive change in score indicates improvement.

Baseline, Day 42, Day 84
Adult ADHD Self-Report Scale (ASRS)
Time Frame: Baseline, Day 42, Day 84

The ASRS v1.1 is an 18-item self-report validated questionnaire designed to assess ADHD symptoms in adults. No total score or diagnostic likelihood is utilized for the twelve questions. Frequency scores are used to determine if the patient has symptoms highly consistent with ADHD in adults. The frequency-based response is more sensitive with certain questions.

Greater frequency indicates higher symptom consistency with ADHD in adults. Negative change indicates improvement.

Baseline, Day 42, Day 84
Patient Health Questionnaire-4 (PHQ-4)
Time Frame: Baseline, Day 42, Day 84

PHQ-4 is an ultra-brief, validated screening assessment for anxiety and depression, consisting of four-items that are scored on a Likert scale of 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day).

A higher score indicates greater levels of depression and anxiety. Negative change indicates improvement.

Baseline, Day 42, Day 84

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
System Usability Scale (SUS)
Time Frame: Day 84
The SUS is a brief, validated 10-item questionnaire that is designed to evaluate a wide variety of products and services, including hardware, software, mobile devices, websites and applications.22 The SUS consists of 10 items rated on a 5-point Likert scale that range from "strongly agree" to "strongly disagree." Results interpretation typically requires normalizing the scores to produce a percentile ranking; however, a SUS score above 68 can generally be considered above average, and a score below 68, generally considered below average.
Day 84

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Caitlin Stamatis, PhD, Akili Interactive Labs, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2024

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

April 17, 2024

First Submitted That Met QC Criteria

April 17, 2024

First Posted (Actual)

April 19, 2024

Study Record Updates

Last Update Posted (Actual)

June 27, 2024

Last Update Submitted That Met QC Criteria

June 25, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Akili-068

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will not be shared with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognition

Clinical Trials on EndeavorOTC®

3
Subscribe